{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:31:05Z","timestamp":1792521065213,"version":"4.5.0"},"reference-count":134,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mutations in the NF1 gene cause Neurofibromatosis Type 1 (NF1), one of the most common genetic disorders. This gene encodes neurofibromin, a member of the GTPase-activating protein (GAP) family that functions as a negative regulator of RAS signaling. Loss of NF1 function leads to persistent RAS activation and promotes tumor growth. The clinical manifestations of NF1 mainly include pigmentary changes, benign and malignant peripheral nerve sheath tumors, as well as gliomas affecting the central nervous system. Currently, MEK inhibition is the only approved therapy and is primarily effective in controlling plexiform neurofibromas (pNFs). However, more comprehensive treatments are needed to address the full spectrum of NF1 manifestations and malignant transformation. Novel therapeutic strategies, including AAV-based gene therapy aimed at restoring NF1 function, oncolytic herpes simplex virus (oHSV) therapy targeting RAS-dysregulated tumor cells, and chimeric antigen receptor T cell (CAR-T) therapy targeting NF1-associated tumors, are under active investigation. In this review, we explore the genetic mechanisms underlying NF1 and highlight recent advances in therapeutic development with a special focus on AAV-based gene therapies alongside other approaches with recent clinical and translational advancements.<\/jats:p>","DOI":"10.3390\/cancers17233788","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:56:41Z","timestamp":1764172601000},"page":"3788","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Neurofibromatosis Type 1: Genetic Mechanisms and Advances in Therapeutic Innovation"],"prefix":"10.3390","volume":"17","author":[{"given":"Yuqing","family":"Lu","sequence":"first","affiliation":[{"name":"Kennedy Krieger Institute, 707 N Broadway, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7587-1992","authenticated-orcid":false,"given":"Manzhu","family":"Xu","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, 707 N Broadway, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9098-1680","authenticated-orcid":false,"given":"Xiaojun","family":"Chen","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, 707 N Broadway, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huazhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, 707 N Broadway, Baltimore, MD 21205, USA"},{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, 707 N Broadway, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2177-0081","authenticated-orcid":false,"given":"Nihao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0760-1725","authenticated-orcid":false,"given":"Karis E.","family":"Weisgerber","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, 707 N Broadway, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-9091","authenticated-orcid":false,"given":"Ren-Yuan","family":"Bai","sequence":"additional","affiliation":[{"name":"Kennedy Krieger Institute, 707 N Broadway, Baltimore, MD 21205, USA"},{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine, 707 N Broadway, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archderm.141.1.71","article-title":"Prevalence of Neurofibromatosis 1 in German Children at Elementary School Enrollment","volume":"141","author":"Lammert","year":"2005","journal-title":"Arch. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-6-11","article-title":"Mortality associated with neurofibromatosis type 1: A study based on Italian death certificates (1995\u20132006)","volume":"6","author":"Masocco","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/jid.2014.465","article-title":"Incidence and Mortality of Neurofibromatosis: A Total Population Study in Finland","volume":"135","author":"Uusitalo","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/356713a0","article-title":"Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients","volume":"356","author":"Basu","year":"1992","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1469-8749.2012.04377.x","article-title":"The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1","volume":"54","author":"Lidzba","year":"2012","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_6","unstructured":"Adam, M.P., Bick, S., and Mirzaa, G.M. (1998). Neurofibromatosis 1. GeneReviews(\u00ae), University of Washington. [Updated 2025]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40265-020-01331-x","article-title":"Selumetinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40265-025-02190-0","article-title":"Mirdametinib: First Approval","volume":"85","author":"Hoy","year":"2025","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102137","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","article-title":"The NF1 somatic mutational landscape in sporadic human cancers","volume":"11","author":"Philpott","year":"2017","journal-title":"Hum. Genom."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.2006.00639.x","article-title":"Neurofibromin: A general outlook","volume":"70","author":"Tajara","year":"2006","journal-title":"Clin. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","article-title":"Clinical and genetic aspects of neurofibromatosis 1","volume":"12","author":"Jett","year":"2010","journal-title":"Genet. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1212\/NXG.0000000000000169","article-title":"Updated nomenclature for human and mouse neurofibromatosis type 1 genes","volume":"3","author":"Anastasaki","year":"2017","journal-title":"Neurol. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Deininger, P.L. (2011). Alu elements: Know the SINEs. Genome Biol., 12.","DOI":"10.1186\/gb-2011-12-12-236"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Alesi, V., Genovese, S., Lepri, F.R., Catino, G., Loddo, S., Orlando, V., Di Tommaso, S., Morgia, A., Martucci, L., and Di Donato, M. (2023). Deep Intronic LINE-1 Insertions in NF1: Expanding the Spectrum of Neurofibromatosis Type 1-Associated Rearrangements. Biomolecules, 13.","DOI":"10.3390\/biom13050725"},{"key":"ref_16","first-page":"297","article-title":"Neurofibromin in neurofibromatosis type 1\u2014Mutations in NF1gene as a cause of disease","volume":"18","author":"Abramowicz","year":"2014","journal-title":"Dev. Period Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cas.13116","article-title":"Mourning Dr. Alfred G. Knudson: The two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex","volume":"108","author":"Hino","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(09)70033-6","article-title":"Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1","volume":"10","author":"Brems","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bergoug, M., Doudeau, M., Godin, F., Mosrin, C., Vall\u00e9e, B., and B\u00e9n\u00e9detti, H. (2020). Neurofibromin Structure, Functions and Regulation. Cells, 9.","DOI":"10.3390\/cells9112365"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1128\/MCB.00019-14","article-title":"Neurofibromatosis type 1 alternative splicing is a key regulator of Ras signaling in neurons","volume":"34","author":"Hinman","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/aja.1002020309","article-title":"Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues","volume":"202","author":"Gutmann","year":"1995","journal-title":"Dev. Dyn."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(96)12730-0","article-title":"Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene","volume":"211","author":"Geist","year":"1996","journal-title":"Neurosci. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0006-291X(02)00501-6","article-title":"The N-terminal splice product NF1-10a-2 of the NF1 gene codes for a transmembrane segment","volume":"294","author":"Kaufmann","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0014-5793(04)00078-X","article-title":"Neurofibromin is actively transported to the nucleus","volume":"560","author":"Vandenbroucke","year":"2004","journal-title":"FEBS Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0021-9258(17)49919-4","article-title":"Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer","volume":"295","author":"Sherekar","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41594-021-00687-2","article-title":"The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1","volume":"28","author":"Lupton","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.molcel.2022.03.011","article-title":"Structural basis of activation of the tumor suppressor protein neurofibromin","volume":"82","author":"Werten","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Napolitano, F., Dell\u2019aquila, M., Terracciano, C., Franzese, G., Gentile, M.T., Piluso, G., Santoro, C., Colavito, D., Patan\u00e8, A., and De Blasiis, P. (2022). Genotype-Phenotype Correlations in Neurofibromatosis Type 1: Identification of Novel and Recurrent NF1 Gene Variants and Correlations with Neurocognitive Phenotype. Genes, 13.","DOI":"10.3390\/genes13071130"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.onc.1209113","article-title":"Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells","volume":"25","author":"Mangoura","year":"2005","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jnr.23189","article-title":"A novel neurofibromin (NF1) interaction with the leucine-rich pentatricopeptide repeat motif-containing protein links neurofibromatosis type 1 and the french canadian variant of leigh\u2019s syndrome in a common molecular complex","volume":"91","author":"Arun","year":"2013","journal-title":"J. Neurosci. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"re1","DOI":"10.1126\/scisignal.2003669","article-title":"Nonredundant Functions for Ras GTPase-Activating Proteins in Tissue Homeostasis","volume":"6","author":"King","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1038\/s41388-019-0809-3","article-title":"Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness","volume":"38","author":"Fadhlullah","year":"2019","journal-title":"Oncogene"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/sj.embor.7400602","article-title":"A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein","volume":"7","author":"Welti","year":"2006","journal-title":"Embo Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jnc.13401","article-title":"Nuclear import mechanism of neurofibromin for localization on the spindle and function in chromosome congression","volume":"136","author":"Koliou","year":"2015","journal-title":"J. Neurochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/febs.13940","article-title":"Syndecans\u2014Key regulators of cell signaling and biological functions","volume":"284","author":"Afratis","year":"2017","journal-title":"FEBS J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Richardson, D.S., Spehar, J.M., Han, D.T., Chakravarthy, P.A., and Sizemore, S.T. (2022). The RAL Enigma: Distinct Roles of RALA and RALB in Cancer. Cells, 11.","DOI":"10.3390\/cells11101645"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ajpath.2013.09.022","article-title":"Ras-Mek-Erk Signaling Regulates Nf1 Heterozygous Neointima Formation","volume":"184","author":"Stansfield","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"a031500","DOI":"10.1101\/cshperspect.a031500","article-title":"Ras-Specific GTPase-Activating Proteins\u2014Structures, Mechanisms, and Interactions","volume":"9","author":"Scheffzek","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1523\/JNEUROSCI.3096-13.2014","article-title":"Neurofibromin Is the Major Ras Inactivator in Dendritic Spines","volume":"34","author":"Oliveira","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/hmg\/ddl023","article-title":"Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras","volume":"15","author":"Hannan","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1093\/hmg\/ddu389","article-title":"Neuronal NF1\/RAS regulation of cyclic AMP requires atypical PKC activation","volume":"23","author":"Anastasaki","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e021800","DOI":"10.1136\/bmjopen-2018-021800","article-title":"Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: A study protocol for a randomised placebo-controlled crossover trial","volume":"8","author":"Barton","year":"2018","journal-title":"BMJ Open"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"B\u00e1ez-Flores, J., Rodr\u00edguez-Mart\u00edn, M., and Lacal, J. (2023). The therapeutic potential of neurofibromin signaling pathways and binding partners. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-04815-0"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Vall\u00e9e, B., Doudeau, M., Godin, F., Gombault, A., Tchalikian, A., de Tauzia, M.-L., and B\u00e9n\u00e9detti, H. (2012). Nf1 RasGAP Inhibition of LIMK2 Mediates a New Cross-Talk between Ras and Rho Pathways. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047283"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Villalonga, E., Mosrin, C., Normand, T., Girardin, C., Serrano, A., \u017dunar, B., Doudeau, M., Godin, F., B\u00e9n\u00e9detti, H., and Vall\u00e9e, B. (2023). LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features. Cells, 12.","DOI":"10.3390\/cells12050805"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1523\/JNEUROSCI.21-11-03764.2001","article-title":"Bipartite interaction between neurofibromatosis type I protein (neurofibromin) and syndecan transmembrane heparan sulfate proteoglycans","volume":"21","author":"Hsueh","year":"2001","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Donarum, E.A., Halperin, R.F., Stephan, D.A., and Narayanan, V. (2006). Cognitive dysfunction in NFI knock-out mice may result from altered vesicular trafficking of APP\/DRD3 complex. BMC Neurosci., 7.","DOI":"10.1186\/1471-2202-7-22"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","article-title":"The NF1 gene in tumor syndromes and melanoma","volume":"97","author":"Kiuru","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ozarslan, B., Russo, T., Argenziano, G., Santoro, C., and Piccolo, V. (2021). Cutaneous Findings in Neurofibromatosis Type 1. Cancers, 13.","DOI":"10.3390\/cancers13030463"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13072-020-00380-6","article-title":"Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK\/p38 signaling","volume":"14","author":"Grit","year":"2021","journal-title":"Epigenetics Chromatin"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Stylianides, C., Hadjigavriel, G., Theotokis, P., Vakirlis, E., Meditskou, S., Manthou, M.E., and Dermitzakis, I. (2025). Epigenetic Mechanisms in Neurofibromatosis Types 1 and 2. Epigenomes, 9.","DOI":"10.3390\/epigenomes9030030"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e168227","DOI":"10.1172\/JCI168227","article-title":"Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor","volume":"133","author":"Jiang","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_55","unstructured":"Uriarte-Arrazola, I., Magall\u00f3n-Lorenz, M., Fern\u00e1ndez-Rodr\u00edguez, J., Zhang, J., Lee, E., Ortega-Bertran, S., Creus-Bachiller, E., Farr\u00e9s-Casas, J., Wilson, K.M., and McKnight, C. (2025). iPSC-derived NF1-CDKN2A-PRC2 deficient neural crest cells mimic glial-to-neuro-mesenchymal transition and form MPNST-like tumors in vivo. bioRxiv, bioRxiv:2025.08.13.670072."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1101\/gr.142604.112","article-title":"Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma","volume":"23","author":"Gutmann","year":"2012","journal-title":"Genome Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11060-025-05024-x","article-title":"Psychosocial functioning and determinants of the health-related quality of life in children with neurofibromatosis type 1 and cognitive impairments","volume":"174","author":"Barton","year":"2025","journal-title":"J. Neuro-Oncol."},{"key":"ref_59","first-page":"398","article-title":"Breast cancer in neurofibromatosis 1: Survival and risk of contralateral breast cancer in a five country cohort study","volume":"22","author":"Evans","year":"2020","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/pbc.25556","article-title":"Rhabdomyosarcomas in children with neurofibromatosis type I: A national historical cohort","volume":"62","author":"Crucis","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: Who\u2019s the driver at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s00381-020-04749-6","article-title":"Craniofacial bone alterations in patients with neurofibromatosis type 1","volume":"36","author":"Beuriat","year":"2020","journal-title":"Child\u2019s Nerv. Syst."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Barreto-Duarte, B., Andrade-Gomes, F.H., Arriaga, M.B., Ara\u00fajo-Pereira, M., Cubillos-Angulo, J.M., and Andrade, B.B. (2021). Association between neurofibromatosis type 1 and cerebrovascular diseases in children: A systematic review. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0241096"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): A multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study","volume":"405","author":"Chen","year":"2025","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of Selumetinib in Neurofibromatosis Type 1\u2013Related Plexiform Neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","article-title":"Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886)","volume":"29","author":"Balagula","year":"2010","journal-title":"Investig. New Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/17407745231207970","article-title":"Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials","volume":"21","author":"Staedtke","year":"2023","journal-title":"Clin. Trials"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.omtn.2022.03.011","article-title":"Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I","volume":"28","author":"Leier","year":"2022","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1097\/j.pain.0000000000001002","article-title":"CRISPR\/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide","volume":"158","author":"Moutal","year":"2017","journal-title":"Pain"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrn.2015.2","article-title":"Applications of CRISPR\u2013Cas systems in neuroscience","volume":"17","author":"Heidenreich","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.omtn.2020.04.012","article-title":"Mutation-Directed Therapeutics for Neurofibromatosis Type I","volume":"20","author":"Leier","year":"2020","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e188932","DOI":"10.1172\/JCI188932","article-title":"A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+\/\u2013 mice","volume":"135","author":"Park","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/21645515.2020.1757989","article-title":"Viral gene delivery vectors: The next generation medicines for immune-related diseases","volume":"17","author":"Diemen","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"120291","DOI":"10.1016\/j.ijpharm.2021.120291","article-title":"Strategies for cancer gene-delivery improvement by non-viral vectors","volume":"596","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy","volume":"240","author":"Schaffer","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"101234","DOI":"10.1016\/j.omtm.2024.101234","article-title":"Novel AAV variants with improved tropism for human Schwann cells","volume":"32","author":"Drouyer","year":"2024","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41434-025-00542-9","article-title":"Engineered AAV capsids mediate transduction of murine neurofibroma and sciatic nerve","volume":"32","author":"Haidar","year":"2025","journal-title":"Gene Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8594","DOI":"10.1038\/s41467-025-63619-4","article-title":"Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors","volume":"16","author":"Bai","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.clinthera.2024.08.009","article-title":"Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions: A Systematic Review and Meta Analysis","volume":"46","author":"Ibrahim","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","article-title":"A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1\u2013associated pediatric low-grade glioma: A Neurofibromatosis Clinical Trials Consortium study","volume":"22","author":"Ullrich","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial","volume":"13","author":"Nalepa","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/pbc.24281","article-title":"Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas","volume":"60","author":"Kim","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-642-54490-3_12","article-title":"Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor","volume":"201","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1016\/j.jtha.2024.07.012","article-title":"Adeno-associated viral vector integration: Implications for long-term efficacy and safety","volume":"22","author":"Batty","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.molmed.2025.01.004","article-title":"Adeno-associated viral vector targeted evolution for neurofibromatosis gene delivery","volume":"31","author":"Henshey","year":"2025","journal-title":"Trends Mol. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1074\/jbc.M009202200","article-title":"Neurofibromin GTPase-activating Protein-related Domains Restore Normal Growth in Nf1\u2212\/\u2212 Cells","volume":"276","author":"Hiatt","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1128\/MCB.01153-08","article-title":"Ral Overactivation in Malignant Peripheral Nerve Sheath Tumors","volume":"29","author":"Bodempudi","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbrc.2006.07.159","article-title":"Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells","volume":"348","author":"Thomas","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41434-019-0080-9","article-title":"Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors","volume":"26","author":"Bai","year":"2019","journal-title":"Gene Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/1566523220666200806111451","article-title":"NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy","volume":"20","author":"Cui","year":"2020","journal-title":"Curr. Gene Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e2208960120","DOI":"10.1073\/pnas.2208960120","article-title":"Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization","volume":"120","author":"Young","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kagiava, A., Richter, J., Tryfonos, C., Leal-Juli\u00e0, M., Sargiannidou, I., Christodoulou, C., Bosch, A., and Kleopa, K.A. (2021). Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-02694-1"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Tanguy, Y., Biferi, M.G., Besse, A., Astord, S., Cohen-Tannoudji, M., Marais, T., and Barkats, M. (2015). Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front. Mol. Neurosci., 8.","DOI":"10.3389\/fnmol.2015.00036"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"102198","DOI":"10.1016\/j.xpro.2023.102198","article-title":"Generation of human iPSC-derived neurofibromaspheres for in vitro and in vivo uses","volume":"4","author":"Mazuelas","year":"2023","journal-title":"STAR Protoc."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/hmg\/ddae144","article-title":"Delivering large genes using adeno-associated virus and the CRE-lox DNA recombination system","volume":"33","author":"Datta","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ymthe.2017.11.019","article-title":"Triple Vectors Expand AAV Transfer Capacity in the Retina","volume":"26","author":"Maddalena","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T Cell Therapy: The Efficacy and Toxicity Balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr. Hematol. Malign- Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: Key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma","volume":"388","author":"Caruana","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40478-025-01965-6","article-title":"Development of CAR-T cell therapy for NF1\/SWN-related nerve sheath tumor treatment","volume":"13","author":"Tang","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Aldrak, N., Alsaab, S., Algethami, A., Bhere, D., Wakimoto, H., Shah, K., Alomary, M.N., and Zaidan, N. (2021). Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells, 10.","DOI":"10.3390\/cells10061541"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.seminoncol.2016.10.005","article-title":"Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers","volume":"43","author":"Grigg","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Tazzyman, S., Stewart, G.R., Yeomans, J., Linford, A., Lath, D., Conner, J., Muthana, M., Chantry, A.D., and Lawson, M.A. (2023). HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models. Viruses, 15.","DOI":"10.3390\/v15030603"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47\u0394: First Approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Kangas, C., Krawczyk, E., and He, B. (2021). Oncolytic HSV: Underpinnings of Tumor Susceptibility. Viruses, 13.","DOI":"10.3390\/v13071408"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/JVI.80.3.1110-1120.2006","article-title":"Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1","volume":"80","author":"Smith","year":"2006","journal-title":"J. Virol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/neuonc\/not317","article-title":"Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus","volume":"16","author":"Antoszczyk","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1158\/1078-0432.CCR-06-0263","article-title":"Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors","volume":"12","author":"Liu","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/21678707.2016.1128322","article-title":"Prospects and progress of oncolytic viruses for treating peripheral nerve sheath tumors","volume":"4","author":"Antoszczyk","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14728222.2018.1465931","article-title":"Emerging therapeutic targets for neurofibromatosis type 1","volume":"22","author":"Walker","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"vdaf065","DOI":"10.1093\/noajnl\/vdaf065","article-title":"Pan-RAS inhibitor RMC-7977 is efficacious in treating NF1-related tumors","volume":"7","author":"Bai","year":"2025","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1535-7163.MCT-07-2335","article-title":"Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors","volume":"7","author":"Johansson","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1038\/s41388-018-0600-x","article-title":"STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma","volume":"38","author":"Fletcher","year":"2018","journal-title":"Oncogene"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1523\/JNEUROSCI.3994-09.2010","article-title":"Defective cAMP Generation Underlies the Sensitivity of CNS Neurons to Neurofibromatosis-1 Heterozygosity","volume":"30","author":"Brown","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/onc.2016.269","article-title":"Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors","volume":"36","author":"Ki","year":"2016","journal-title":"Oncogene"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-3167","article-title":"Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors","volume":"78","author":"Peacock","year":"2018","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Staedtke, V., Gray-Bethke, T., Riggins, G.J., and Bai, R.-Y. (2020). Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1. Genes, 11.","DOI":"10.3390\/genes11070762"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00262-020-02548-1","article-title":"Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target","volume":"69","author":"Farschtschi","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/2326-6066.CIR-19-0072","article-title":"PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor","volume":"7","author":"Davis","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Khan, B., Qahwaji, R.M., Alfaifi, M.S., and Mobashir, M. (2024). Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16060732"},{"key":"ref_128","first-page":"873","article-title":"A novel HDAC11 inhibitor potentiates the tumoricidal effects of cordycepin against malignant peripheral nerve sheath tumor through the Hippo signaling pathway","volume":"12","author":"Huang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Zhang, X., Murray, B., Mo, G., and Shern, J.F. (2020). The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor. Genes, 11.","DOI":"10.3390\/genes11030287"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41416-020-0903-x","article-title":"Translating current basic research into future therapies for neurofibromatosis type 1","volume":"123","author":"Brosseau","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Zhou, M., and Shen, Z. (2025). Advanced progress in the genetic modification of the oncolytic HSV-1 virus. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1525940"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41417-025-00931-7","article-title":"Barriers and solutions for CAR-T therapy in solid tumors","volume":"32","author":"Tu","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Weber, T. (2021). Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.658399"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2024.12.054","article-title":"Understanding the interplay between oHSV and the host immune system: Implications for therapeutic oncolytic virus development","volume":"33","author":"Ayele","year":"2024","journal-title":"Mol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3788\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:35:25Z","timestamp":1764308125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/23\/3788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":134,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17233788"],"URL":"https:\/\/doi.org\/10.3390\/cancers17233788","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}